Associated Papers
PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications.
Jiang P et al.
Journal of Translational Medicine, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Blombery P et al.
Leukemia, 2025
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
Gruessner C et al.
Leukemia & Lymphoma, 2025
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
Garcia M et al.
Annals of Hematology, 2025
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
Woyach JA et al.
Blood, 2024
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Pozzo F et al.
Leukemia, 2024
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Woolston DW et al.
Haematologica, 2024
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
Brown J et al.
Research Square, 2024
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
Chirino A et al.
Genes, 2023
Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer's disease.
Tsai AP et al.
Immunity, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
Woyach JA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
Tatarczuch M et al.
Blood Advances, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S et al.
Blood Advances, 2023
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
Gao F et al.
Cancer Medicine, 2023
The Conformational State of the BTK Substrate PLCγ Contributes to Ibrutinib Resistance.
Joseph RE et al.
Journal of Molecular Biology, 2022
The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration.
Jackson JT et al.
The Journal of Biological Chemistry, 2021
A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
Raghunathan V et al.
European Journal of Haematology, 2021
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE et al.
Frontiers in Immunology, 2021
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.
Gao F et al.
Frontiers in Genetics, 2021
Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics.
Penter L et al.
Frontiers in Immunology, 2021
Phospholipase C families: Common themes and versatility in physiology and pathology.
Katan M et al.
Progress in Lipid Research, 2020
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Ondrisova L et al.
Frontiers in Oncology, 2020
Genomic landscape of platinum resistant and sensitive testicular cancers.
Loveday C et al.
Nature Communications, 2020
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Gángó A et al.
International Journal of Cancer, 2020
Structural insights and activating mutations in diverse pathologies define mechanisms of deregulation for phospholipase C gamma enzymes.
Liu Y et al.
Ebiomedicine, 2020
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
American Journal of Hematology, 2019
Functional characterization of phospholipase C-γ2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder.
Walliser C et al.
Oncotarget, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Dynamic Allostery in PLCγ1 and Its Modulation by a Cancer Mutation Revealed by MD Simulation and NMR.
Koss H et al.
Biophysical Journal, 2018
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Lampson BL et al.
Expert Review of Hematology, 2018
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Landau DA et al.
Nature Communications, 2017
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Saba NS et al.
Cancer Research, 2017
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
Jones D et al.
Leukemia, 2017
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Albitar A et al.
Oncotarget, 2017
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
Walliser C et al.
The Journal of Biological Chemistry, 2016
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Burger JA et al.
Nature Communications, 2016
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM et al.
Blood, 2015
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Daver N et al.
Blood, 2015